Skip to main content
    C

    CorMedix Inc (CRMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.82
    +0.16 (+3.43%)

    Market Cap: $370.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CorMedix Inc (CRMD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    CorMedix reported revenue of $297.84M for the fiscal year ended Dec 31, 2025, up 585.1% from the year before. That year, net income was $163.06M with a net margin of 54.7%, operating cash flow was $175.05M and free cash flow was $172.79M. The quarter ended Sep 30, 2026 had revenue of $54.52M and net income of -$14.72M.

    Revenue and Margins

    The operating margin was 50.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $224.10K, a compound annual rate of 122.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$297.84M+585.1%92.6%50.4%54.7%
    Dec 2024$43.47MN/A92.7%-51.4%-41.2%
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$65.41K-65.7%94.3%-46819.9%-45409.9%
    Dec 2021$190.94K-20.2%22.0%-15417.5%-14774.7%
    Dec 2020$239.23K-15.5%14.4%-11378.4%-9207.7%
    Dec 2019$283.27K-34.1%-31.8%-7416.3%-5801.3%
    Dec 2018$429.80K+30.5%7.7%-6250.4%-6242.4%
    Dec 2017$329.33K+47.0%65.1%-9997.4%-10023.4%
    Dec 2016$224.10KN/A-63.6%-11048.8%-10996.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$297.84M$43.47M$0$65.41K$190.94K$239.23K$283.27K$429.80K$329.33K$224.10K
    Cost of revenue$22.09M$3.03M$0$3.73K$148.94K$204.85K$373.23K$396.79K$114.96K$366.67K
    Gross profit$275.75M$40.28M$0$61.67K$42.00K$34.38K-$89.97K$33.01K$214.36K-$142.57K
    Research and development$19.33M$3.94M$13.16M$10.68M$13.13M$13.38M$11.05M$18.82M$24.49M$15.74M
    Operating income$150.14M-$22.36M-$48.96M-$30.62M-$29.44M-$27.22M-$21.01M-$26.86M-$32.92M-$24.76M
    Net income$163.06M-$17.93M-$46.34M-$29.70M-$28.21M-$22.03M-$16.43M-$26.83M-$33.01M-$24.64M
    EBITDA$164.34M-$21.41M-$48.78M-$30.38M-$29.28M-$27.03M-$20.64M-$26.79MN/A-$24.74M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$54.52M$101.93M$127.43M$118.37M$104.28M$39.74M$39.08M$31.21M$11.46M$806.12K$0$304.11K
    Gross profit$30.00M$77.13M$105.12M$107.31M$93.08M$37.87M$37.48M$30.03M$10.77M$296.28K-$818.54K-$53.51K
    Operating income-$6.62M$42.91M$63.66M$59.13M$51.35M$19.54M$20.13M$12.94M-$3.29M-$15.30M-$16.70M-$15.67M
    Net income-$14.72M$25.99M$38.60M$14.02M$108.56M$19.83M$20.64M$13.46M-$2.78M-$14.15M-$14.47M-$14.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $146.07M exceeded cash and equivalents by $1.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$826.14M$118.85M$82.06M$62.04M$68.95M$49.31M$29.48M$18.83M$13.45M$21.91M
    Current assets$367.05M$114.58M$79.45M$59.55M$66.47M$48.18M$29.35M$18.67M$13.27M$21.83M
    Cash and equivalents$144.84M$40.65M$43.64M$43.15M$53.32M$41.91M$16.35M$17.62M$10.38M$8.06M
    Total liabilities$420.83M$34.19M$11.92M$6.98M$6.15M$5.09M$5.83M$13.89M$6.26M$4.09M
    Short-term debt$1.45M$167.92K$150.62K$134.80K$121.37K$109.13K$2.01KN/AN/A$1.83K
    Long-term debt$144.63M$0N/AN/AN/AN/AN/A$6.13M$0$0
    Shareholder equity$405.31M$84.66M$70.14M$55.06M$62.80M$44.22M$23.65M$4.93M$7.19M$17.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$917.75M$904.05M$815.64M$826.14M$750.86M$252.60M$149.58M$118.85M$77.59M$57.73M$68.02M$82.06M
    Total liabilities$456.04M$443.22M$378.59M$420.83M$376.73M$31.97M$34.69M$34.19M$18.87M$11.55M$10.01M$11.92M
    Cash and equivalents$355.15M$256.69M$178.09M$145.82M$48.49M$159.31M$66.29M$40.65M$35.29M$28.54M$35.18M$43.64M
    Shareholder equity$461.71M$460.83M$437.05M$405.31M$374.13M$220.63M$114.89M$84.66M$58.71M$46.18M$58.01M$70.14M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.7% of operating cash flow. Share repurchases came to 3.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$175.05M-$50.62M-$38.41M-$24.36M-$21.16M-$21.97M-$15.05M-$23.70M-$28.59M-$22.27M
    Capital expenditures$2.26M$116.00K$327.30K$219.36K$1.43M$112.64K$36.57K$48.89K$151.99K$58.72K
    Free cash flow$172.79M-$50.73M-$38.74M-$24.58M-$22.58M-$22.08M-$15.09M-$23.75M-$28.74M-$22.32M
    Share repurchases$5.73M$0N/AN/AN/AN/A$226.85KN/AN/AN/A
    Investing cash flow-$308.43M$21.23M-$17.06M-$3.71M-$9.13M$7.43M-$12.02M$1.56M$10.36M$11.42M
    Financing cash flow$238.45M$26.32M$55.92M$17.90M$41.76M$40.10M$25.80M$29.40M$20.52M$7.09M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$89.70M$86.24M$42.38M$94.46M$30.86M$29.99M$19.74M-$5.61M-$13.65M-$14.04M-$17.31M-$10.75M
    Capital expenditures$1.91M$561.00K$729.00K$1.72M$506.00K$24.00K$10.00K$10.14K$9.77K$34.79K$61.31K$295.93K
    Free cash flow$87.79M$85.68M$41.65M$92.74M$30.35M$29.97M$19.73M-$5.63M-$13.66M-$14.07M-$17.37M-$11.04M
    Last 12 quarters

    Frequently Asked Questions About CRMD

    What is CorMedix's annual revenue?

    CorMedix reported revenue of $297.84M for the fiscal year ended Dec 31, 2025.

    How fast is CorMedix's revenue growing?

    Revenue was up 585.1% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is CorMedix profitable?

    Yes. CorMedix reported net income of $163.06M for the fiscal year ended Dec 31, 2025, with a net margin of 54.7%.

    How much free cash flow does CRMD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $175.05M minus capital expenditures of $2.26M produced free cash flow of $172.79M.

    How much debt does CorMedix have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $144.63M, short-term debt of $1.45M and cash and equivalents of $144.84M.